

ABOUT REINVENTING DRUG DISCOVERY

For over 30 years, our mission has been to use the power of science to bring new medicines to patients... over and over again.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, nearly all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic diseases, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary *VelociSuite*® technologies, such as *VelociImmune*®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.

Samsung v. Regeneron
IPR2023-00442
U.S. Pat. 10,130,681, Exhibit 2246



Every day, we apply our
technologies and research
people with serious diseases
us.

2020 was a challenging but inspiring year: from creating a new medicine in record time while advancing a diverse pipeline to delivering needed medicines despite pandemic conditions.



 [2020 Annual Report](#)



 [2020 Responsibility Report](#)

[Regeneron News: Oct 22nd](#)

[Dupixent® \(dupilumab\) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this](#)

Follow us:     

Regeneron by the numbers

30+

years of scientific leadership

9K+

employees worldwide

~1.1K+

employees with an MD, PhD
or PharmD degree

3rd

consecutive year as one of
Fast Company Best
Workplaces for Innovators

#1

ranking in *Science*
magazine's global Top
Employer survey for six of the
past nine years

3,000+

volunteers for virtual Day for
Doing Good 2020

9

FDA-approved medicines

98%

of our waste diverted from
landfill, surpassing our 2025
global responsibility goal

~100%

of drug candidates invented
and developed in-house

1.4M+

exomes sequenced to date

175+

peer-reviewed publications in
2020

30+

product candidates in clinical
development across multiple
therapeutic areas



Honors and awards

Fast Company: Best Workplaces for Innovators, 2021

Great Place To Work: Fortune 100 Best Companies to Work For, 2021

Great Place to Work Ireland: Best Workplaces, 2021

Great Place to Work Ireland: Best Workplaces for Women, 2021

Fast Company: World Changing Ideas (Pandemic Response), 2021

IDEA Pharma: Pharmaceutical Invention Index, 2021

Science: Top Employer, 2020

Fortune: Change the World, 2020

Forbes: JUST Companies, 2020

Dow Jones Sustainability World Index, 2020

Dow Jones Sustainability North American Index, 2020

Newsweek: America's Most Responsible Companies, 2020

Civic 50: Most Community-Minded Companies in the Nation, 2020

Great Places to Work: Best Workplace in Ireland, 2020



Led by science

We are the only biopharma company founded and led by physician-scientists since the beginning, more than three decades ago. From our first days, science was and remains our central guiding principle. Our leadership includes multiple Nobel Laureates and five members of the National Academy of Sciences, and we are one of the first companies to form a Science and Technology Committee as an integral component of its Board, a practice which has since become industry standard.

[GET TO KNOW THE TEAM](#)



Featured perspectives

The stories and opinions behind our work.



[RAISING THE BAR FOR CORPORATE RESPONSIBILITY IN THE BIOTECH INDUSTRY](#)



By: Hala Mirza
Senior Vice President, Corporate
Communications and Citizenship



[WORKING TOGETHER TO PROVIDE COVID-19 TESTING COMPONENTS](#)



By: Dan Van Plew
Executive Vice President and
General Manager, Industrial
Operations and Product Supply

[MORE PERSPECTIVES](#)



A look back

Science isn't easy and new medicines aren't made over night. Decades of investment and perseverance have brought us to where we are today.

[VIEW OUR HISTORY](#)





Contact us

See our U.S. and European locations and contact information.

[GET IN TOUCH](#)



A broad spectrum of collaborations

Learn about our clinical-stage research partnerships and see how we're changing the landscape of medicine.

[LEARN MORE](#)



Industrial Operations and Product Supply

Grounded in excellence and driven to continuously improve, our industry-leading IOPS team is responsible for the production of our many medicines.

[EXPLORE OUR OPERATIONS](#)



REGENERON
SCIENCE TO MEDICINE®



[Terms of Use](#)

[Contact Us](#)
[Site Map](#)

[Social Media Terms of Engagement](#)

[Privacy Notice](#)
[Accessibility Statement](#)

[INVESTORS AND MEDIA](#) >

[CAREERS](#) >

[IRELAND](#) >

[COVID-19 ANTIBODY PROGRAM](#) >

Copyright © 2021 Regeneron Pharmaceuticals Inc. All rights reserved. All trademarks mentioned are the property of their respective owners.